Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups

Epidemiology and Infection

Volumn 134, Issue 2, 2006, Pages 211-221

  Leung, G M ^a,b   Lim, W W ^c   Ho, L M ^a   Lam, T H ^a   Ghani, A C ^d   Donnelly, C A ^d   Fraser, C ^d   Riley, S ^d   Ferguson, N M ^d   Anderson, R M ^d   Hedley, A J ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Public Health Laboratory Centre   (Hong Kong)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY;

ARTICLE; BLOOD DONOR; CHINA; CONFIDENCE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GEOGRAPHIC DISTRIBUTION; HONG KONG; HUMAN; IMMUNOFLUORESCENCE TEST; INFECTION RISK; POPULATION RESEARCH; SARS CORONAVIRUS; SERODIAGNOSIS; SEROPREVALENCE; SINGAPORE; SYSTEMATIC REVIEW; WESTERN BLOTTING;

ANTIBODY FORMATION; BLOOD DONORS; GEOGRAPHY; HEALTH PERSONNEL; HUMANS; IMMUNOGLOBULIN G; SARS VIRUS; SEROEPIDEMIOLOGIC STUDIES; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 33244460572     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268805004826     Document Type: Article

References (51)

1. Breiman RF, Evans MR, Preiser W, et al. Role of China in the quest to define and control severe acute respiratory syndrome. Emerg Infect Dis 2003; 9: 1037-1041.
2. Riley S, Fraser C, Donnelly CA, et al. Transmission dynamics of the etiological agent of severe acute respiratory syndrome (SARS) in Hong Kong: The impact of public health interventions. Science 2003; 300: 1961-1966.
3. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003; 362: 1353-1358.
4. Leung GM, Chung PH, Tsang T, et al. SARS-CoV antibody prevalence in all Hong Kong patient contacts. Emerg Infect Dis 2004; 10: 1653-1656.
5. Woo PC, Lau SK, Tsoi HW, et al. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet 2004; 363: 841-845.
6. Hunink M, Glasziou P, Siegel J, et al. Decision making in health and medicine: Integrating evidence and values. Cambridge: Cambridge University Press: 2001.
7. WHO. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS), 2003 (http://www.who.int/csr/sars/en/WHOconsensus.pdf). World Health Organisation. Accessed 29 June 2004.
8. Centers for Disease Control and Prevention. Prevalence of IgG antibody to SARS-associated coronavirus in animal traders - Guangdong Province, China, 2003. Morb Mortal Wkly Rep 2003; 52: 986-987.
9. Chan PK, Ip M, Ng KC, et al. Severe acute respiratory syndrome-associated coronavirus infection. Emerg Infect Dis 2003; 9: 1453-1454.
10. Chan FKL, Ching JYL, Wong WE, et al. A population-based study of the seroprevalence of asymptomatic SARS-associated coronavirus infection in Hong Kong. Hospital Authority Convention 2004 - Hong Kong SARS Forum Special Issue on SARS Abstracts; 2004, p. 85.
11. Chow PK, Ooi EE, Tan HK, et al. Healthcare worker seroconversion in SARS outbreak. Emerg Infect Dis 2004; 10: 249-250.
12. Gold WL, Mederski B, Rose D, et al. Prevalence of asymptomatic (AS) infection by Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in exposed healthcare workers (HCW). Abstracts from the 2003 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
13. Ho KY, Singh KS, Habib AG, et al. Mild illness associated with severe acute respiratory syndrome coronavirus infection: Lessons from a prospective sero-epidemiologic study of health-care workers in a teaching hospital in Singapore. J Infect Dis 2004; 189: 642-647.
14. Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 2003; 349: 508-509.
15. Li LH, Shi YL, Li P, et al. Detection and analysis of SARS coronavirus-specific antibodies in sera from non-SARS children. Di Yi Jun Yi Da Xue Xue Bao 2003; 23: 1085-1087.
16. Liu YN, Fan BX, Fang XQ, Yu BX, Chen LA. The quantitative detection of anti-coronavirus antibody titer in medical personnel closely contacted with severe acute respiratory syndrome patients. Zhonghua Jie He He Hu Xi Za Zhi 2003; 26: 583-585.
17. Seto WH, Ng TK, Lai ST, Yam L, Lw KI, Chan JCK. Sero-surveillance of healthcare workers in clinical areas with SARS patients. Hospital Authority Convention 2004 - Hong Kong SARS Forum Special Issue on SARS Abstracts, 2004: 84.
18. Wang ZH, Nong Y, Lin JT, et al. Covert infection of severe acute respiratory syndrome in health-care professionals and its relation to the workload and the type of work. Zhonghua Jie He He Hu Xi Za Zhi 2004; 27: 151-154.
19. Xu HF, Wang M, Zhang ZB, et al. An epidemiologic investigation on infection with severe acute respiratory syndrome coronavirus in wild animals traders in Guangzhou. Zhonghua Yu Fang Yi Xue Za Zhi 2004; 38: 81-83.
20. Yu WC, Tsang TH, Tong WL, et al. Prevalence of subclinical infection by the SARS coronavirus among general practitioners in Hong Kong. Scand J Infect Dis 2004; 36: 287-290.
21. Zheng BJ, Wong KH, Zhou J, et al. SARS-related virus predating SARS outbreak, Hong Kong. Emerg Infect Dis 2004; 10: 176-178.
22. Sharp S, Sterne J. Corrections to the meta-analysis command. Stata Tech Bull 1998; STB-43: 84.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials (1986). Control Clin Trials 1986; 7: 177-188.
24. Last JM. The iceberg. 'Completing the clinical picture' in general practice. Lancet 1963; 2: 28-31.
25. Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003; 361: 1701-1703.
26. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302: 276-278.
27. Lipsitch M, Cohen T, Cooper B, et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 2003; 300: 1966-1970.
28. Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004; 303: 1666-1669.
29. Yeh SH, Wang HY, Tsai CY, et al. Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution. Proc Natl Acad Sci USA 2004; 101: 2542-2547.
30. Young M. Prevalence of non-pneumonic infections with SARS-correlated virus. Lancet 2004; 363: 1826.
31. Yu IT, Li Y, Wong TW, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 2004; 350: 1731-1739.
32. Lin M, Tseng HK, Trejaut JA, et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 2003; 4: 9.
33. Hill AVS. The immunogenetics of human infectious disease. Annu Rev Immunol 1998; 16: 593-617.
34. Liu C, Carrington M, Kaslow RA, et al. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2003; 187: 1404-1410.
35. Collins AR. Human coronavirus OC43 interacts with major histocompatibility complex class I molecules at the cell surface to establish infection. Immunol Invest 1994; 23: 313-321.
36. Woo PC, Lau SK, Wong BH, et al. Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol 2004; 42: 2306-2309.
37. Che XY, Qiu LW, Pan YX, et al. Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. J Clin Microbiol 2004; 42: 2629-2635.
38. van der Hoek L, Pyre K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004; 10: 368-373.
39. Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005; 79: 884-895.
40. Ebihara T, Endo R, Ma X, Ishiguro N, Kikuta H. Detection of human coronavirus NL63 in young children with bronchiolitis. J Med Virol 2005; 75: 463-465.
41. Arden KE, Nissen MD, Sloots TP, Mackay IM. New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia. J Med Virol 2005; 75: 455-462.
42. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953-1966.
43. Sun ZF, Meng XJ. Antigenic cross-reactivity between the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus and polyclonal antisera of antigenic group I animal coronaviruses: implication for SARS diagnosis. J Clin Microbiol 2004; 42: 2351-2352.
44. Woo PC, Lau SK, Wong BH, et al. False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide. J Clin Microbiol 2004; 42: 5885-5888.
45. Holmes KV, Enjuanes L. Virology. The SARS coronavirus: A postgenomic era. Science 2003; 300: 1377-1378.
46. Snijder EJ, Bredenbeek PJ, Dobbe JC, et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 2003; 331: 991-1004.
47. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300: 1394-1399.
48. Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science 2003; 300: 1399-1404.
49. Yip CW, Hon CC, Zeng F, Chow KYC, Leung FCC. Prevalence of non-pneumonic infections with SARS-correlated virus. Lancet 2004; 363: 1825.
50. Zhou YH. Prevalence of non-pneumonic infections with SARS-correlated virus. Lancet 2004; 363: 1825-1826.
51. Theron M. Prevalence of non-pneumonic infections with SARS-correlated virus. Lancet 2004; 363: 1825.